Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk (NCT07347977) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
China1,400 participantsStarted 2026-01-01
Plain-language summary
The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.
Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age range: 18-80 years old.
✓. Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer
✓. Is willing and capable of providing consent.
Exclusion criteria
✕. Palliative surgery without intention of cure.
✕. Extensive comorbidities (ASA IV).
✕. Patients with known or suspected allergy to lidocaine.
✕. Patients who are currently pregnant or breastfeeding.
✕. Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.
✕. Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.
✕
What they're measuring
1
Disease-Free Survival (DFS)
Timeframe: Up to 36 months after operation
Trial details
NCT IDNCT07347977
SponsorFirst Affiliated Hospital of Ningbo University
. Currently, there is severe renal insufficiency (serum creatinine ≥451umol/L or glomerular filtration rate (calculated using the MDRD formula) \<30ml/min).